{
    "clinical_study": {
        "@rank": "112677", 
        "arm_group": [
            {
                "arm_group_label": "Bioavailability", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Elimination & PK", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This 2-arm, open-label, non-randomized study will investigate the absolute bioav ailability,\n      pharmacokinetics, mass balance, and routes of elimination of GDC-003 2 as well as its safety\n      in healthy volunteers. Patients will receive either a si ngle oral dose of GDC-0032 followed\n      by a 14C-labeled IV dose of GDC-0032 or a si ngle oral dose of 14C-labelled GDC-0032."
        }, 
        "brief_title": "A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index (BMI) 18 to 32 kg/m2, inclusive;\n\n          -  Healthy, as judged by physician from medical history, 12-lead ECG, vital signs, and\n             clinical laboratory evaluations;\n\n          -  Agree to use effective contraceptive methods as defined by protocol;\n\n          -  Negative hepatitis panel and HIV screen;\n\n          -  Sufficient bowel movements (minimum of 1 per day).\n\n        Exclusion Criteria:\n\n          -  History or clinical manifestation of: any major medical disorders; any\n             food/drug/substance allergies;\n\n          -  History of stomach or intestinal surgery or resection except for appendectomy and/or\n             hernia repair;\n\n          -  History of alcoholism or drug addiction within 1 year prior to drug administration;\n\n          -  Tobacco or nicotine use within 6 months prior to study start;\n\n          -  Chronic use of gastric acid inhibitors within 6 months of study start or use of\n             gastric acid inhibitors and/or antacids within 1 month prior to drug administration;\n\n          -  Evidence of malabsorption syndrome or other condition interfering with\n             gastrointestinal absorption;\n\n          -  Inability or unwillingness to swallow capsules;\n\n          -  Participation in a drug study in which a drug was administered within 30 days prior\n             to study start;\n\n          -  Participation in more than one radiolabeled drug study within 12 months preceding\n             drug administration. The previous radiolabeled study drug must have been received\n             more than 6 months prior to this study, and the total exposure from this study and\n             the previous study is less than 5000 mrem whole body annual exposure;\n\n          -  Exposure to significant radiation within 12 months prior to study start."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967966", 
            "org_study_id": "GP28755"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Bioavailability", 
                    "Elimination & PK"
                ], 
                "description": "Single oral dose", 
                "intervention_name": "GDC-0032", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Bioavailability", 
                "description": "Single IV dose", 
                "intervention_name": "GDC-0032", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A PHASE 1 STUDY TO INVESTIGATE THE ABSOLUTE BIOAVAILABILITY OF GDC-0032 AND THE ABSORPTION, METABOLISM, AND EXCRETION OF [14C]-GDC-0032 IN HEALTHY MALE SUBJECTS", 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Bioavailability: Absolute bioavailability of GDC-0032 (Area under the concentration-time curve [AUC])", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 11"
            }, 
            {
                "measure": "Elimination & PK: Amount of drug excreted in urine/feces over the sampling interval", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 22"
            }, 
            {
                "measure": "Elimination & PK: Maximum concentration (Cmax) of GDC-0032", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 22"
            }, 
            {
                "measure": "Elimination & PK: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 22"
            }, 
            {
                "measure": "Elimination & PK: Total radioactivity concentrations in whole blood, plasma, urine, and feces.", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 22"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967966"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Elimination & PK: Metabolite identification in plasma, urine, & feces", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 22"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "38 to 49 days"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}